ArticleAIDS care2026
Contraceptive method continuation among a prospective cohort study of Malawian women on antiretroviral treatment initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable for pregnancy prevention (the FP-ART study).
Article in AIDS care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Limited prospective data exist for long-term hormonal contraceptive continuation rates among women living with HIV. We conducted a prospective cohort study of women living with HIV in Lilongwe, Malawi from 2017 to 2021 and evaluated their contraceptive method continuation and ART regimens. Participants initiating either depot medroxyprogesterone acetate (DMPA) injection or levonorgestrel (LNG) implant were followed every 24 weeks for up to 192 weeks. 1,359 participants enrolled in the study; 689 initiated the DMPA injection, and 670 initiated the LNG implant. At enrollment, DMPA and implant users had similar age, body mass index, educational levels, number of children, breastfeeding status, future pregnancy intention, CD4 count, and HIV viral load. 1,179 participants (86.8%) usedefavirenz-based therapy at enrollment, with 874 (74.1%) switching to dolutegravir-based therapy by their last study visit. During study follow-up, 225 (32.7%) DMPA and 141 (21.0%) implant users discontinued their initial contraceptive method. Time to method discontinuation differed between the two contraceptive groups (log-rank
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.